Compare DexCom, Inc. (DXCM) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs EPAM Systems Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while EPAM Systems Inc trades at $113.24 (market cap $5.87B). The key difference: DexCom, Inc. is far larger — about 5.4× EPAM Systems Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and EPAM Systems Inc for 37 Days on average.
| DXCM | EPAM | |
|---|---|---|
Market Cap | $31.86B | $5.87B |
Volume | 3,607,070 | 847,420 |
Sector | Health | Technology |
52-Week High | $92.34 | $221.40 |
52-Week Low | $54.84 | $76.04 |
Typical Hold Time | 62 Days | 37 Days |
Enterprise Value | $31.32B | $5.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
EPAM Systems trades at $113.86, up 5.11% today, with strong technical momentum as the stock approaches resistance near $115. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.46B in 2025, though net margins compressed to 6.92%. Recent news highlights EPAM's cloud infrastructure achievements and activist investor pressure for share buybacks.
The outlook remains cautiously optimistic with a consensus price target of $119 offering 4.5% upside. Key risks include North American growth slowdown and AI disruption to legacy services. Analyst sentiment is predominantly bullish (59% Buy ratings), but investors should monitor Q3 earnings and management's response to shareholder value concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
